![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Semiconductor ETF
SMH
4
The Technology Select Sector SPDR® Fund
XLK
5
Invesco Solar ETF
TAN
US Stock MarketDetailed Quotes
Valneva (VALN)
- 5.570
- -0.140-2.45%
Trading May 19 09:55 ET
528.17MMarket Cap-2.99P/E (TTM)
5.610High5.570Low6.61KVolume5.610Open5.710Prev Close37.02KTurnover0.01%Turnover RatioLossP/E (Static)94.82MShares12.25052wk High5.91P/B436.85MFloat Cap5.06052wk Low--Dividend TTM78.43MShs Float67.840Historical High--Div Yield TTM0.70%Range %3.620Historical Low5.600Avg Price1Lot Size
VALN Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
VALN Orderflow
Unit: --
VALN Orderflow Trend
IntradayDayWeekMonth
No Data
Valneva (VALN) News
H.C. Wainwright Maintains Valneva(VALN.US) With Buy Rating, Maintains Target Price $18
Valneva Earnings Call: Pipeline Progress, Profits Under Pressure
Valneva Tightens 2026 Guidance and Restructures as Lyme Vaccine Nears Regulatory Filings
Valneva Q1 Earnings Call Highlights
Valneva SE (VALN) Q1 2026 Earnings Call Transcript Summary
Transcript: Valneva Q1 2026 Earnings Conference Call
Valneva (VALN) Stock Forum
$Valneva (VALN.US)$
tmr is the day
tmr is the day
$Valneva (VALN.US)$
accumulating!!!!
accumulating!!!!
$Valneva (VALN.US)$
accumulating or traps ?
accumulating or traps ?
$Valneva (VALN.US)$ $Pfizer (PFE.US)$ Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Preventing Lyme Disease In Individuals Aged Five Years And...
Benzinga
Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Prev...
Benzinga
Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Prev...
1
$Valneva (VALN.US)$ Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ
GlobeNewswire
01:00
Long-lasting antibody persistence was comparable in older (65+) and younger adults
Long-term antibody persistence is a key competitive advantage
for a vaccine targeting unpredictable outbreak diseases like chikungunya
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positiv...
GlobeNewswire
01:00
Long-lasting antibody persistence was comparable in older (65+) and younger adults
Long-term antibody persistence is a key competitive advantage
for a vaccine targeting unpredictable outbreak diseases like chikungunya
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positiv...
3
8
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)